Month: September 2026

News

Sun Life launches Disability with Health Navigator to improve health outcomes and provide ongoing health support for employees

September 30, 2026 BCBN Comments Off on Sun Life launches Disability with Health Navigator to improve health outcomes and provide ongoing health support for employees

WELLESLEY, Mass., Sept. 30, 2026 /PRNewswire/ — Sun Life U.S. now offers Disability with Health Navigator, strengthening employer health plans by providing personalized care navigation to employees, whether they are facing a disabling health condition or simply looking for health support…. … […]

No Picture
News

In HelloNation, ABA Therapy Expert Rob Shapiro Explains the Roles of BCBAs, Behavior Technicians, and RBTs on ABA Therapy Teams

September 30, 2026 BCBN Comments Off on In HelloNation, ABA Therapy Expert Rob Shapiro Explains the Roles of BCBAs, Behavior Technicians, and RBTs on ABA Therapy Teams

The article clarifies how each member of an ABA therapy team supports skill development and coordinated care for Massachusetts families. FITCHBURG, Mass., Sept. 30, 2026 /PRNewswire/ — Who does what on a child’s ABA therapy team, and how do these roles work together to support progress?… … […]

No Picture
News

Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne

September 30, 2026 BCBN Comments Off on Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today presented new data at the 31st Annual Congress of the World Muscle Society (WMS) that provide evidence of clinically meaningful functional benefit of ELEVIDYS (delandistrogene moxeparvovec) in older ambulatory patients with Duchenne muscular dystrophy…. … […]

No Picture
News

Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer

September 30, 2026 BCBN Comments Off on Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer

NEEDHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced novel immunological biomarker data from the ongoing phase 2 PrTK05 trial (… […]

No Picture
News

Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026

September 30, 2026 BCBN Comments Off on Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026

NEEDHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the presentation of new biomarker data from its completed phase 3 clinical trial… … […]